Here, we provide evidence that the velcrin BAY 2666605 promotes potent antileukemic effects in in vitro and in vivo AML models via modulation of SLFN12 activity through complex formation with either PDE3A or phosphodiesterase 3B (PDE3B). This evidence concerns the gene PDE3A and acute myeloid leukemia.